RTTNews | Feb 11, 2021 10:12AM EST

10:11 Thursday, February 11, 2021 (RTTNews.com) - Shares of AC Immune SA (ACIU) are currently gaining 35% on Thursday morning after the Switzerland-based clinical-stage biopharmaceutical company announced positive interim results from ongoing mid-stage trial in older patients with early Alzheimer's disease.

ACIU is currently trading at $9.91, up $2.60 or 35.57%, on the Nasdaq.

AC Immune announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its anti-phospho-Tau vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease.

ACI-35.030 vaccination, a collaboration with Janssen Pharmaceuticals of Johnson & Johnson (JNJ), generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels.

No clinically relevant adverse events were observed.

In September, AC Immune shares tanked after its mid-stage study evaluating Semorinemab in early alzheimer's disease failed to meet primary goals.

Read the original article on RTTNews ( https://www.rttnews.com/3169128/stock-alert-ac-immune-up-35-on-positive-interim-results-from-alzheimer-s-drug-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved